Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21098975> ?p ?o }
Showing triples 1 to 58 of
58
with 100 triples per page.
- Q21098975 subject Q20740287.
- Q21098975 subject Q7335370.
- Q21098975 subject Q8256003.
- Q21098975 subject Q8297683.
- Q21098975 subject Q8431759.
- Q21098975 subject Q8791920.
- Q21098975 subject Q9052323.
- Q21098975 abstract "Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and reduced central nervous system permeation. Apalutamide binds weakly to the GABAA receptor similarly to enzalutamide, but due to its relatively lower central concentrations, may have a lower risk of seizures in comparison. The drug has been found to be effective and well-tolerated in clinical trials thus far, with the most common side effects reported including fatigue, nausea, abdominal pain, and diarrhea. Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.Recently, the acquired F876L mutation of the AR identified in advanced prostate cancer cells was found to confer resistance to both enzalutamide and apalutamide. A newer antiandrogen, ODM-201, is not affected by this mutation, nor has it been found to be affected by any other tested/well-known AR mutations.Apalutamide may be effective in a subset of prostate cancer patients with acquired resistance to abiraterone acetate.".
- Q21098975 atcPrefix "None".
- Q21098975 casNumber "956104-40-8".
- Q21098975 iupacName "4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide".
- Q21098975 pubchem "24872560".
- Q21098975 thumbnail Apalutamide.svg?width=300.
- Q21098975 wikiPageExternalLink 800032695.
- Q21098975 wikiPageWikiLink Q14873015.
- Q21098975 wikiPageWikiLink Q15408409.
- Q21098975 wikiPageWikiLink Q181257.
- Q21098975 wikiPageWikiLink Q183425.
- Q21098975 wikiPageWikiLink Q186889.
- Q21098975 wikiPageWikiLink Q1996756.
- Q21098975 wikiPageWikiLink Q2066956.
- Q21098975 wikiPageWikiLink Q20707196.
- Q21098975 wikiPageWikiLink Q20740287.
- Q21098975 wikiPageWikiLink Q21098941.
- Q21098975 wikiPageWikiLink Q30612.
- Q21098975 wikiPageWikiLink Q321431.
- Q21098975 wikiPageWikiLink Q3269441.
- Q21098975 wikiPageWikiLink Q40878.
- Q21098975 wikiPageWikiLink Q47273.
- Q21098975 wikiPageWikiLink Q5156356.
- Q21098975 wikiPageWikiLink Q5518498.
- Q21098975 wikiPageWikiLink Q574820.
- Q21098975 wikiPageWikiLink Q58929.
- Q21098975 wikiPageWikiLink Q60147.
- Q21098975 wikiPageWikiLink Q6279182.
- Q21098975 wikiPageWikiLink Q6581305.
- Q21098975 wikiPageWikiLink Q7180990.
- Q21098975 wikiPageWikiLink Q7335370.
- Q21098975 wikiPageWikiLink Q824258.
- Q21098975 wikiPageWikiLink Q8256003.
- Q21098975 wikiPageWikiLink Q8297683.
- Q21098975 wikiPageWikiLink Q8431759.
- Q21098975 wikiPageWikiLink Q8791920.
- Q21098975 wikiPageWikiLink Q9052323.
- Q21098975 wikiPageWikiLink Q9635.
- Q21098975 wikiPageWikiLink Q9690.
- Q21098975 atcPrefix "None".
- Q21098975 casNumber "956104".
- Q21098975 iupacName "4".
- Q21098975 pubchem "24872560".
- Q21098975 type ChemicalSubstance.
- Q21098975 type Drug.
- Q21098975 type ChemicalObject.
- Q21098975 type Thing.
- Q21098975 type Q8386.
- Q21098975 comment "Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and reduced central nervous system permeation.".
- Q21098975 label "Apalutamide".
- Q21098975 depiction Apalutamide.svg.